AASLD 2015 Dinner Program Series

AASLD_Invite_Dinner_BKG_v4

6:00 - 6:30 PM: Check-in/Walk-in Registration 6:30 - 8:30 PM: Program and Q&A

 AASLD 2015 Pre Register Button

 

About the Program:

Program Overview:

The Advances in Chronic Hepatitis C: Management and Treatment program is a comprehensive, expert review of the 66th American Association for the Study of Liver Diseases Annual Meeting (AASLD 2014). This program consists of six components: (1) CME Internet Symposium: AASLD 2015 Expert Review: a 1.5 hour Internet symposium that features an overview and discussion of key presentations and posters, selected by the expert faculty discussants; (2) CME Internet Symposium: European Perspective on AASLD 2015: a 1-hour Internet symposium featuring Europe-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in the EU; (3) CME Internet Symposium: Brazilian Perspective on AASLD 2015: a 1-hour Internet symposium featuring Brazil-based expert faculty reviewing and discussing key presentations with a focus on management and treatment in Brazil; (4) Comprehensive Expert Review and Discussion of Key Presentations: an on-line, in-depth review of 8 of the key poster/presentations reviewed in the Internet symposium (5) Rapid-Fire Review of AASLD 2015: a podcast that provides a brief, audio summary of the most essential data presented at the conference; and (6) HCV in 2015 - From Conference To Clinic: Reviewing And Applying Data From AASLD 2015: case-based dinner meetings during which the key data are reviewed, discussed and applied to patient care.

HCV in 2015 - From Conference to Clinic: Reviewing and Applying Data From AASLD 2015 is an interactive, case-based dinner program series designed to highlight and discuss the clinical significance and application of new findings in HCV medicine presented at AASLD 2015. Because the focus of the dinner programs will be on case studies and applying the data presented at AASLD 2015 in a clinical setting, prior to attending a dinner program participants will be asked to view the CME Internet Symposium: AASLD 2015 Review, which will familiarize them with the AASLD 2015 data and serve as a comprehensive conference overview and summary. As a result of this blended learning approach, participants will gain an increased understanding of key data presented at AASLD 2015 and be better prepared to address their HCV patients’ health needs and provide optimal care in a clinical setting.

All online components of the program will be accessible at www.viraled.com.

This program is produced by the Postgraduate Institute for Medicine and ViralEd, Inc. It is not a session created by or presented at AASLD 2015 and it is not sanctioned by the organizers of AASLD 2015.

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Educational Objectives:

After completing this activity, the participant should be better able to:

  • Use in a clinical setting important findings from key studies on CHC diagnosis and treatment presented at AASLD 2015
  • Employ current treatment protocols for CHC in clinical practice, including the studies and data presented at AASLD 2015, to improve patient care
  • Engage patients and colleagues in a discussion on studies and data presented at AASLD 2015 relevant to new therapies for CHC to determine the appropriate treatment for patients with CHC
Back to Top

Program Dates and Locations:

Tuesday, December 1, 2015
Baltimore, MD
Tuesday, December 1, 2015
San Francisco, CA

Wednesday, December 2, 2015
Los Angeles, CA

Thursday, December 3, 2015
Boston, MA

Thursday, December 3, 2015
New York, NY

Thursday, December 3, 2015
Anaheim, CA
Tuesday, December 8, 2015
Houston, TX
Wednesday, December 9, 2015
Miami, FL
Thursday, December 10, 2015
Phoenix, AZ
Tuesday, December 15, 2015
Chicago, IL
Back to Top

Program Faculty:

Nezam H. Afdhal, MD
Professor of Medicine
Harvard School of Medicine
Beth Israel Deaconess Medical Center
Boston, Massachusetts

Maurizio Bonacini, MD
Director, HIV-Liver Clinic
Department of Transplantation
California Pacific Medical Center
San Francisco, California
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease
Professor of Medicine
University of Miami’s School of Medicine
Miami, Florida

Richard A. Manch, MD, FACP, FACG
Chief of Hepatology
St. Joseph’s Hospital and Medical Center
Clinical Professor of Medicine
Creighton University School of Medicine
– Phoenix Regional Campus
Phoenix, Arizona

Sammy Saab, MD
Professor of Medicine and Surgery
The Pfleger Liver Institute
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California

Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

John M. Vierling, MD
Professor of Medicine
Professor of Surgery
Chief of Hepatology
Director of Advanced Liver Therapies
St. Luke’s HospitalDirector of Baylor Liver Health
Houston, Texas
Back to Top

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

The Postgraduate Institute for Medicine designates this live activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Back to Top

Sunshine Act:

As of August 1, 2013, pharmaceutical companies are required by the open payments act (AKA Sunshine Act) to account for certain transfers of value provided to physicians. The federal guidance for the Sunshine Act provides exceptions for CME expenses that meet certain criteria. We believe the program to which you are invited meets these exce ptions, and therefore we will not be collecting, nor reporting, any information gathered from this program. If federal guidance is further clarified in the future, we will then pro vide that information to the supporting pharmaceutical companies to the best of our ability.

Back to Top

PIM_small

VE logo 300px 

 

 

 

This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.


Prepare to print

Share this page:

Get link code to this page     


Back to Top